Skip to main content
TipRanks
Go Ultimate75% OFF

ABIONYX Pharma SA (0RAG) AI Stock Analysis

0 Followers
GB:0RAG

ABIONYX Pharma SA

(LSE:0RAG)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Positive EquityDespite significant erosion, the company still reports positive equity, providing a remaining capital base to support operations and development. This is a limited but durable financial cushion while management works toward reducing losses and improving the balance sheet.
Negative Factors
Severe Operating LossesVery large operating losses relative to revenue show that the business has not yet demonstrated sustainable economics. The scale of the deficit makes profitability dependent on substantial revenue growth, cost restructuring, or improved product economics, increasing execution risk over the next several quarters.

ABIONYX Pharma SA (0RAG) vs. iShares MSCI United Kingdom ETF (EWC)

-80%-60%-40%-20%0%20%40%GB:0RAG-63.31%EWC+8.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 62.34M
Dividend Yield
―
Average Volume (3M)
482
Price to Earnings (P/E)
-6.4
Beta (1Y)
0.42
Revenue Growth
-10.38%
EPS Growth
-72.05%
Country
UK
Employees
49
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

ABIONYX Pharma SA Business Overview & Revenue Model

Company Description

ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This...

ABIONYX Pharma SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0RAG against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:SIGHTFR:SIGHT42NeutralEUR 18.44M-1.0352.39%―-610.31%43.88%
FR:ALSENFR:ALSEN41NeutralEUR 71.15M-1.66-54.15%――6.26%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%GB:0RAGFR:ALCOXFR:SIGHTFR:ALSENDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0RAG and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0RAGABIONYX Pharma SA1.57-2.55-61.85%
FR:ALCOXNicox SA0.27-0.03-10.07%
FR:SIGHTGenSight Biologics0.07-0.03-30.56%
FR:ALSENSensorion SAS7.04-9.41-57.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.